Qyuns Therapeutics (HKG:2509) said its unit Jiangsu Cellularforce Biopharma has successfully passed the EU Qualified Person audit, confirming that its industrialization base meets European Union Good Manufacturing Practice standards, according to an Oct. 10 Hong Kong bourse filing.
Shares of the firm were down over 8% in Monday afternoon trade.
The audit, conducted over three days by a senior EU QP under EudraLex Volume 4 guidelines, recognized the unit's high-quality management system, advanced facilities, and technical capabilities.